Back to top
more

Align Technology (ALGN)

(Delayed Data from NSDQ)

$212.15 USD

212.15
651,165

+1.37 (0.65%)

Updated Nov 5, 2024 04:00 PM ET

After-Market: $211.69 -0.46 (-0.22%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value B Growth C Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 29% (72 out of 250)

Industry: Medical - Dental Supplies

Zacks News

Wright Medical Group (WMGI) Q2 Loss Narrower than Expected

Wright Medical Group N.V. (WMGI) posted narrower-than-expected loss on account of strong growth in the U.S.

    Inogen (INGN) Beats Earnings and Revenue Estimates in Q2

    Inogen (INGN) delivers better-than-expected results in Q2 with significant contributions from the Business-to-Business segment. Moreover, raised guidance buoys optimism.

      Illumina (ILMN) Rides on New Products, Low Margin a Concern

      Illumina (ILMN) continues to grow in high-potential genetic research market through innovation and product launches.

        Bruker (BRKR) Q2 Earnings & Revenues Beat Estimates, View Up

        Bruker (BRKR) delivers a better-than-expected Q2, largely driven by strength in CALID Group and BEST. Moreover, a raised guidance buoys optimism.

          Kevin Cook headshot

          Bull of the Day: Align Technology (ALGN)

          The clear winner in alternative dental alignment continues to make long-term investors smile

            Hologic (HOLX) Beats on 3Q Earnings, Cuts Revenue Guidance

            Hologic's (HOLX) revenue growth in molecular diagnostics and GYN Surgical offset by poor blood screening and Breast Imaging show.

              Cardiovascular Systems (CSII) Posts Q4 Earnings, Revenues Top

              Cardiovascular Systems' (CSII) lower operating expenses drove the year-over-year improvement in Q4 earnings.

                Genomic Health (GHDX) Posts Wider-than-Expected Loss in Q2

                Genomic Health (GHDX) continues to lag expectations despite strong adoption of its Oncotype DX test.

                  Illumina (ILMN) Tops Q2 Earnings & Revenues, Raises View

                  Illumina (ILMN) delivers an impressive Q2 on strong uptake of sequencing consumables and microarrays and continued adoption of NovaSeq platform. A raised guidance buoys optimism.

                    ResMed (RMD) Q4 Earnings Top, 2020 Strategic Goals on Track

                    ResMed's Q4 results (RMD) register strong sales in sleep devices, respiratory care devices, mask systems and software solutions.

                      DaVita (DVA) Beats Earnings and Revenue Estimates in Q2

                      DaVita's (DVA) stable performance across its businesses was the key highlight of the second quarter.

                        VWR Corp (VWR) Beats Earnings & Revenue Estimates in Q2

                        VWR Corp (VWR) reported an impressive Q2 and is presently awaiting a merger with Avantor.

                          IDEXX Laboratories (IDXX) Q2 Earnings & Revenues Top, View Up

                          IDEXX Laboratories (IDXX) rides high on strength across all segments in Q2 with significant contributions from the Companion Animal Group business. Moreover, a raised guidance buoys optimism.

                            Hill-Rom Holdings (HRC) Beats Q3 Earnings, Misses Revenues

                            Hill-Rom Holdings (HRC) rides high on international growth and product innovation.

                              Company News For July 31, 2017

                              Companies in the news are: EXPE,MRK,ALGN,MAT

                                NuVasive (NUVA) Beats on Q2 Earnings, Retains 2017 View

                                NuVasive (NUVA) rides high on continued growth in international business in Q2. Also, the company has worked on revamping its organizational structure.

                                  Omnicell (OMCL) Earnings Meet, Revenues Beat Estimates in Q2

                                  Omnicell (OMCL) benefited from high XT revenues and strength in IV Solutions in Q2.

                                    AmerisourceBergen (ABC) Q3 Earnings: Will It Disappoint?

                                    AmerisourceBergen's (ABC) third-quarter performance face risks from reduced contract renewals and lower generic inflation.

                                      Abaxis (ABAX) Misses Earnings & Revenue Estimates in Q1

                                      Despite Abaxis' lackluster performance in the fiscal first quarter, its new marketing strategies and recent launches buoy optimism.

                                        GNC Holdings (GNC) Tops Q2 Earnings, Misses Sales Estimates

                                        Sluggish performance by the U.S. & Canada international and manufacturing/wholesale segments marred second-quarter results for GNC Holdings (GNC).

                                          Align Technology (ALGN) Beats on Q2 Earnings and Revenues

                                          Align Technology (ALGN) rides high in Q2 banking on robust growth in the Invisalign space.

                                            QIAGEN (QGEN) Beats on Earnings & Sales in Q2, Raises View

                                            QIAGEN (QGEN) continues to bank on the Molecular Diagnostics space for growth.

                                              Merit Medical Systems (MMSI) Worth a Look: Stock Gains 7.7%

                                              Merit Medical Systems, Inc. (MMSI) shares rose almost 8% in the last trading session.

                                                McKesson (MCK) Misses Earnings Estimates in Q1, Raises View

                                                McKesson's (MCK) performance was muted in the first quarter owing to branded to generic conversions and competition in its pharmacy business.

                                                  Integra LifeSciences (IART) Q2 Earnings Meet, Revenues Miss

                                                  Integra LifeSciences' (IART) solid performance in the Orthopedics and Tissue Technologies was the key highlight of the second quarter.